KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Nektar Therapeutics (NKTR) Restructuring Costs: 2022-2023

Historic Restructuring Costs for Nektar Therapeutics (NKTR) over the last 2 years, with Dec 2023 value amounting to $1.9 million.

  • Nektar Therapeutics' Restructuring Costs fell 31.54% to $1.9 million in Q4 2023 from the same period last year, while for Dec 2023 it was $5.5 million, marking a year-over-year decrease of 95.38%. This contributed to the annual value of $5.5 million for FY2023, which is 82.67% down from last year.
  • Nektar Therapeutics' Restructuring Costs amounted to $1.9 million in Q4 2023, which was up 189.26% from $652,000 recorded in Q3 2023.
  • Nektar Therapeutics' 5-year Restructuring Costs high stood at $106.0 million for Q2 2022, and its period low was $652,000 during Q3 2023.
  • In the last 2 years, Nektar Therapeutics' Restructuring Costs had a median value of $1.7 million in 2023 and averaged $15.5 million.
  • Data for Nektar Therapeutics' Restructuring Costs shows a peak YoY increase of 8.34% (in 2023) and a maximum YoY decrease of 98.72% (in 2023) over the last 5 years.
  • Over the past 2 years, Nektar Therapeutics' Restructuring Costs (Quarterly) stood at $2.8 million in 2022, then slumped by 31.54% to $1.9 million in 2023.
  • Its last three reported values are $1.9 million in Q4 2023, $652,000 for Q3 2023, and $1.4 million during Q2 2023.